Newman Dignan & Sheerar, Inc. Tcr2 Therapeutics Inc. Transaction History

Newman Dignan & Sheerar, Inc.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Jan 20, 2023	BUY	$0.83 - $1.44 $830 - $1,440	1,000 Added 8.68%	12,522 $0
Q3 2022 Oct 18, 2022	BUY	$1.86 - $3.75 $21,430 - $43,207	11,522 New	11,522 $21,000
Q2 2022 Aug 03, 2022	SELL	$2.11 - $2.94 $23,258 - $32,407	-11,023 Closed	0 $0
Q1 2022 Apr 14, 2022	BUY	$2.4 - $4.71 $26,455 - $51,918	11,023 New	11,023 $30,000

Ticker TCRR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,606,400
Description
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical tria...

Get notified when there are updates to the investment portfolio of Newman Dignan & Sheerar, Inc., based on Form 13F filings with the SEC.

Stay updated on Newman Dignan & Sheerar, Inc. with notifications on news.